Back to discover
Drug

coagulation factor X, human

Established medicine
ClassCoagulation factor X exogenous proteinResearchOngoing clinical research
Also known as Coagadex, Coagulation Factor X (Pooled Human Plasma), Coagulation factor X, FACTOR X,HUMAN+7 more

Coagadex, Coagulation Factor X (Pooled Human Plasma), Coagulation factor X, FACTOR X,HUMAN, Factor X, Factor X (stuart prower factor), Human coagulation factor X, Kcentra, Stuart-prower factor, COAGULATION FACTOR X HUMAN, Coagulation factor X (human).

RxNorm1426166ChEMBLCHEMBL4297951ATCB02BD13UNII0P94UQE6SY
Coagulation factor X
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
coagulation factor X, human
Aliases & brands
CoagadexCoagulation Factor X (Pooled Human Plasma)Coagulation factor XFACTOR X,HUMANFactor XFactor X (stuart prower factor)Human coagulation factor XKcentraStuart-prower factorCOAGULATION FACTOR X HUMANCoagulation factor X (human)
RxNorm CUI
1426166
ChEMBL ID
CHEMBL4297951
ATC codes
B02BD13
UNII
0P94UQE6SY
Primary mechanism
Coagulation factor X exogenous protein

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Coagulation factor X
F10 · P00742
EXOGENOUS PROTEINCoagulation factor X exogenous protein

Clinical trials

1 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
1
registered trials across all phases
LATEST COMPLETION 2013
1
Late-stage (III+)
1
Completed
PHASE DISTRIBUTIONn = 1
Phase 31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.

CompletedPH IIIBio Products Laboratoryn=162013

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.

CompletedPH IIIBio Products Laboratoryn=162013
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials